β-Caryophyllene inhibits cell proliferation in dexmedetomidine treated cells
There is an urgent need to look for new anti-tumor targets for treating lung tumor successfully
(Liu et al., 2017). The present study was carried out to look for the possible role of β-Caryophyllene against dexmedetomidine induced cell proliferation in lung cancer cells. First of all, we investigated the impact of β-Caryophyllene on proliferation of dexmedetomidine treated lung cancer cell line using MTT assay
(Wang et al., 2018). As shown in Fig 1, β-Caryophyllene treatment significantly inhibited proliferation of A549 cells compared to dexmedetomidine treatment and control.
β-Caryophyllene induces apoptosis in dexmedetomidine treated cells
Cell survival and death are mainly decided by the expression dynamics of pro- and anti-apoptotic proteins. Expression levels of pro-apoptotic proteins like caspases get up-regulated during cell death
(Bartke et al., 2001). To look for the underlying mechanism of β-Caryophyllene-induced death in A549 cells, western blotting was carried out (Fig 2A). As shown in (Fig 2B) caspase-3/9 levels and cleaved PARP gets increased after β-Caryophyllene treatment in dexmedetomidine challenged cells. Densitometry analysis (Fig 2C) showed that β-Caryophyllene treatment increases expression levels of caspase-3 by 2.8 and 2 fold compared to dexmedetomidine treatment and control respectively. Expression level of caspase-9 was increased by 2.7 and 1.4 fold with β-Caryophyllene treatment compared to dexmedetomidine treatment and control respectively. Similarly, it was observed that β-Caryophyllene increases expression levels of cleaved PARP by 4 and 2 fold compared to dexmedetomidine treatment and control respectively.
β-Caryophyllene prevents cell migration in dexmedetomidine treated cells
The effects of β-Caryophyllene treatment on A549 cell migration was assessed with the wound-healing assay (Fig 3A, B). We found that the migration of A549 cells is inhibited by 2 and 1.5 folds with β-Caryophyllene treatment compared to dexmedetomidine treatment and control respectively.
β-Caryophyllene causes p-AMPK activation in dexmedetomidine treated cells
Various metabolic stresses induce AMP-activated protein kinase (AMPK) activation through its phosphorylation of threonine 172 (
Mihaylova and Shaw 2011;
He et al., 2014). AMPK activation through inhibition of the mTOR pathway leads to reduced proliferation of cells
(Dowling et al., 2007; Kimura et al., 2003). To look for expression levels of p-AMPK, Cells were either treated with dexmedetomidine alone or together with β-Caryophyllene for 24 h. It was observed that β-Caryophyllene treatment significantly increased expression of p-AMPK in dexmedetomidine treated cells (Fig 4A). Densitometry analysis (Fig 4B) showed that β-Caryophyllene treatment increases expression levels of p-AMPK by 3.5 and 1.7 fold respectively compared to dexmedetomidine treatment and control respectively.
β-Caryophyllene increases mitochondrial proliferation and PGC-1α/TFAM expression in dexmedetomidine treated cells
Changes in copy number of mitochondrial DNA (mtDNA) have been well reported in human cancers
O’Hara et al., (2019) Reznik et al., (2016). To look for impact of treatments on the mtDNA copies, cells were either treated with dexmedetomidine alone or together with β-Caryophyllene for 24 h. It was found that β-Caryophyllene treatment significantly increased mtDNA copies compared to dexmedetomidine treatment (Fig 5A). Expression levels of PGC-1Q and TFAM were determined after treating cells with either dexmedetomidine alone or together with β-Caryophyllene for 24 h. It was observed that β-Caryophyllene treatment significantly increased expression of PGC-1Q (Fig 5B) and TFAM (Fig 5D) compared to dexmedetomidine treatment only. Densitometry analysis showed that β-Caryophyllene treatment increases expression levels of PGC-1Q by 5.5 and 2.5 fold compared to dexmedetomidine treatment and control respectively (Fig 5C). Similarly, β-Caryophyllene treatment increases expression levels of TFAM by 6 and 3.5 fold respectively compared to dexmedetomidine treatment and control respectively (Fig 5E).
β-Caryophyllene counters dexmedetomidine associated tumor growth in lung cancer mice model
In vivo antitumor ability of β-Caryophyllene was determined in mice model of A549 cell xenograft (Fig 6A). It was observed that β-Caryophyllene treatment of A549 cell implanted models inhibits tumor growth significantly compared to dexmedetomidine treated and control groups. However, it was observed that β-Caryophyllene treatment did not affect body weight of mice during study period (Fig 6B).